CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Endo International PLC is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Endo International PLC High Risk Report!
Minerva House, Simmonscourt Road
Phone: +353 12682000p:+353 12682000 DUBLIN, 000 00  Ireland Ticker: ENDPQENDPQ
Filed for Bankruptcy on 8/16/2022
Case #22-22549, filed in the U.S. Bankruptcy Court for the Southern District of New York (White Plains)
Business Summary
Endo International plc is a specialty pharmaceutical company. The Company operates through four business segments: Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals and International Pharmaceuticals. Its Branded Pharmaceuticals segment includes a variety of branded products in the areas of urology, orthopedics, endocrinology, medical aesthetics and bariatrics, among others. Its products include XIAFLEX, SUPPRELIN LA, NASCOBAL Nasal Spray, AVEED, QWO, PERCOCET, TESTOPEL and EDEX, among others. Its Sterile Injectables segment consists of branded sterile injectable products such as VASOSTRICT, ADRENALIN and APLISOL, among others, and certain generic sterile injectable products, including ertapenem for injection and ephedrine sulfate injection, among others. The Company’s Generic Pharmaceuticals segment consists of a product portfolio including solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmics and sprays.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202312/31/2023YesYesYesYesYes

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Non-Executive Chairman of the Board Mark G.Barberio 60 6/10/2021 2/19/2020
President, Chief Executive Officer, Director BlaiseColeman 49 3/6/2020 11/22/2016
Chief Financial Officer, Executive Vice President Mark T.Bradley 54 3/6/2020 3/6/2020
9 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Astora Women's Health Ireland Limited First Floor, Minerva House Ballsbridge Ireland
Endo Eurofin Unlimited Company First Floor, Minerva House Ballsbridge Ireland
Endo Global Biologics Limited First Floor, Minerva House Dublin Ireland
45 additional Subsidiary records available in full report.

Business Names
Business Name
70 Maple Avenue, LLC
Actient Pharmaceuticals LLC
Actient Therapeutics, LLC
103 additional Business Names available in full report.

General Information
Number of Employees: 2,931 (As of 2/28/2024)
Outstanding Shares: 235,219,612 (As of 2/28/2024)
Shareholders: 199
Stock Exchange: OTC
Federal Tax Id: 680683755


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, April 19, 2024